- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00919854
A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children
3. april 2014 oppdatert av: Tibotec Pharmaceuticals, Ireland
A Phase II, Open Label Trial, to Evaluate Pharmacokinetics, Safety, Tolerability and Antiviral Activity of DRV in Combination With Low-Dose Ritonavir (DRV/Rtv) in Treatment-Experienced HIV-1 Infected Children From 3 Years to Below 6 Years of Age
The purpose of this study is to evaluate the pharmacokinetics (what the body does to the medication), safety and antiviral activity to support dose recommendations by body weight of darunavir with low-dose ritonavir (DRV/rtv), in combination with other antiretroviral drugs (ARVs), in treatment-experienced Human immunodeficiency virus 1 (HIV 1) infected children.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is an open-label (all people know the identity of the intervention), study to evaluate the pharmacokinetics, safety and antiviral activity.
Approximately 24 HIV-1 infected children will be enrolled in this study.
The study consists of a 4-week screening period, a 48-week treatment period, and a 4-week follow-up period.
Participants will receive DRV/rtv according to their body weight.
Safety evaluations will include assessment of adverse events, laboratory tests, physical Examination, neurologic examination, vital signs, and electrocardiogram.
The total duration of the study will be 56 weeks.
Studietype
Intervensjonell
Registrering (Faktiske)
27
Fase
- Fase 2
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Buenos Aires, Argentina
-
-
-
-
-
Rio De Janeiro, Brasil
-
Sao Paulo, Brasil
-
-
-
-
-
Chennai, India
-
-
-
-
-
Kilifi, Kenya
-
-
-
-
-
Durban, Sør-Afrika
-
Johannesburg, Sør-Afrika
-
Johannesburg Gauteng, Sør-Afrika
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
3 år til 6 år (Barn)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Participants with a documented HIV 1 infection (by any of the local standard diagnostic methods, such as HIV PCR-DNA, ELISA or western blot (WB) test for HIV antibodies, etc.)
- Body weight from 10 kg to less than 20 kg at screening
- Participants currently on stable ART (anti retroviral therapy) for at least 12 weeks, who need to change their ARV regimen because it is currently failing, with a viral load of greater than 1000 copies/mL
- Screening genotype resistance test results showing less than 3 DRV resistance-associated mutations
- Parents or legal representative willing and able to give consent
Exclusion Criteria:
- Participants with presence of any currently active conditions included in the listing of WHO ( World Health Organisation) Clinical Stage 4 and participants with presence of a non-HIV encephalopathy
- Administration of any ARV (antiretroviral) or non-ARV investigational medication or investigational vaccine within 30 days prior to screening, except for those medications where dose recommendations for children are available
- Life expectancy less than 6 months, according to the judgment of the investigator
- Co-enrollment in other clinical and/or cohort trials without written permission of the Sponsor
- Participants with any active clinically significant disease (eg, tuberculosis [TB], cardiac dysfunction, pancreatitis, acute viral infections) or findings during screening of medical history or physical examination that, in the investigator's opinion, would compromise the subject's safety or outcome of the study
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Darunavir (DRV)+Ritonavir (rtv)
Before dose adjustment, oral darunavir suspension (100 mg/mL): 20 mg per kg body weight twice daily for children weighing between 10 and <20 kg.
After dose adjustment, 25 mg per kg body weight twice daily if weight less than 15 kg, and fixed dose of 375 mg twice daily if weight more than or equal to 15 kg.
Before dose adjustment, oral ritonavir solution (80 mg/mL): 3 mg per kg body weight twice daily and after dose adjustment fixed dose of 50 mg twice daily if weight more than or equal to 15 kg.
|
Darunavir oral suspension (100 mg/mL) will be administered as 20 mg per kg body weight twice daily for children weighing between 10 and <20 kg before dose adjustment.
Darunavir oral suspension will be administered 25 mg per kg body weight twice daily if weight less than 15 kg, and fixed dose of 375 mg darunavir tablets twice daily if weight more than or equal to 15 kg after dose adjustment.
Ritonavir oral solution (80 mg/mL) will be administered as 3 mg per kg body weight twice daily before dose adjustment and after dose adjustment fixed dose of 50 mg twice daily if weight more than or equal to 15 kg.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Number of Participants With Virological Response (Viral Load Less Than 50 Copies/mL) at Week 24 - Time to Loss of Virologic Response (TLOVR)
Tidsramme: Week 24
|
The TLOVR algorithm was used to derive response, ie, response and loss of response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders after discontinuation.
Participants with intermittent missing viral load values were considered responders if the preceeding and succeeding visits indicated response.
In all other cases, intermittent values were imputed with nonresponse.
Resuppression after confirmed virologic failure was considered as failure in this algorithm.
|
Week 24
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Number of Participants With Virological Response (Viral Load Less Than 50 Copies/mL) at Week 48
Tidsramme: Week 48
|
Week 48
|
Number of Participants With Virological Response (Viral Load Less Than 400 Copies/mL) at Week 24 and Week 48
Tidsramme: Week 24 and Week 48
|
Week 24 and Week 48
|
Number of Participants With Less Than or Equal to 1 log10 Decrease in Plasma Viral Load at Week 24 and Week 48
Tidsramme: Week 24 and Week 48
|
Week 24 and Week 48
|
Mean Change From Baseline to Week 24 and Week 48 in Plasma log10 Viral Load
Tidsramme: Baseline, Week 24 and Week 48
|
Baseline, Week 24 and Week 48
|
Mean Change From Baseline to Week 24 and Week 48 in CD4+ Percentage
Tidsramme: Baseline, Week 24 and Week 48
|
Baseline, Week 24 and Week 48
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. september 2009
Primær fullføring (Faktiske)
1. august 2010
Studiet fullført (Faktiske)
1. februar 2011
Datoer for studieregistrering
Først innsendt
11. juni 2009
Først innsendt som oppfylte QC-kriteriene
11. juni 2009
Først lagt ut (Anslag)
12. juni 2009
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
23. april 2014
Siste oppdatering sendt inn som oppfylte QC-kriteriene
3. april 2014
Sist bekreftet
1. april 2014
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- RNA-virusinfeksjoner
- Virussykdommer
- Infeksjoner
- Blodbårne infeksjoner
- Smittsomme sykdommer
- Seksuelt overførbare sykdommer, virale
- Seksuelt overførbare sykdommer
- Lentivirus infeksjoner
- Retroviridae-infeksjoner
- Sykdommer i immunsystemet
- Langsomme virussykdommer
- HIV-infeksjoner
- Ervervet immunsviktsyndrom
- Immunologiske mangelsyndromer
- Molekylære mekanismer for farmakologisk virkning
- Anti-infeksjonsmidler
- Antivirale midler
- Enzymhemmere
- Anti-HIV-midler
- Antiretrovirale midler
- Proteasehemmere
- Cytokrom P-450 CYP3A-hemmere
- Cytokrom P-450 enzymhemmere
- HIV-proteasehemmere
- Virale proteasehemmere
- Ritonavir
- Darunavir
Andre studie-ID-numre
- CR012553
- TMC114-TiDP29-C228 (Annen identifikator: Tibotec Pharmaceuticals, Ireland)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Humant immunsviktvirus 1
-
Washington University School of MedicineMerck Sharp & Dohme LLCTilbaketrukketHuman T-celle Leukemi Virus Type 1 Infeksjon
-
University of California, BerkeleyHealth for a Prosperous Nation; Tanzania Ministry of Health, Community... og andre samarbeidspartnereAktiv, ikke rekrutterendeHIV (Human Immunodeficiency Virus)Tanzania
-
Columbia UniversityNational Institute of Mental Health (NIMH); Ministry of Health and Social...FullførtHIV (Human Immunodeficiency Virus) | AIDS (ervervet immunsviktsyndrom)Tanzania
-
Columbia UniversityFullførtHIV (Human Immunodeficiency Virus)Forente stater
-
University of California, BerkeleyNational Institute of Mental Health (NIMH); Ministry of Health, Tanzania; Management and Development for Health og andre samarbeidspartnereAktiv, ikke rekrutterende
-
Columbia UniversityNational Institute of Allergy and Infectious Diseases (NIAID); New York... og andre samarbeidspartnereFullførtHIV (Human Immunodeficiency Virus)Swaziland
-
Columbia UniversityNational Institute of Nursing Research (NINR)FullførtHIV (Human Immunodeficiency Virus) | AIDS (ervervet immunsviktsyndrom)Forente stater
-
Columbia UniversityMinistry of Health, SwazilandFullført
-
University of California, BerkeleyNational Institute of Mental Health (NIMH); Ministry of Health, Tanzania; Management and Development for Health og andre samarbeidspartnereRekruttering
-
University of PennsylvaniaNational Institute of Mental Health (NIMH)FullførtSeksuelt overførbare sykdommer | HIV (Human Immunodeficiency Virus)Forente stater
Kliniske studier på Darunavir
-
Shanghai Public Health Clinical CenterUkjentKoronavirus | Lungebetennelse, PneumocystisKina
-
Janssen-Cilag International NVFullførtHIV-infeksjoner | Humant immunsviktvirus | Ervervet immunsviktsyndromvirus | AIDS-virusStorbritannia, Belgia, Tyskland, Spania, Portugal, Israel, Danmark, Den russiske føderasjonen, Østerrike, Ungarn, Sveits
-
Hamad Medical CorporationFullførtLungebetennelse | COVID | KoronavirusQatar
-
Janssen Research & Development, LLCFullført
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Fullført
-
Therapeutic ConceptsJanssen Scientific Affairs, LLCUkjent
-
Centre de Recherches et d'Etude sur la Pathologie...FullførtHIV-infeksjoner | HIV-1 infeksjonFrankrike
-
Germans Trias i Pujol HospitalFundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y...Fullført